Anavex Life Sciences (STU:12X1) Ending Cash Position : €128.24 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences Ending Cash Position?

Anavex Life Sciences's Ending Cash Position for the quarter that ended in Mar. 2024 was €128.24 Mil.

Anavex Life Sciences's quarterly Ending Cash Position declined from Sep. 2023 (€141.51 Mil) to Dec. 2023 (€131.83 Mil) and declined from Dec. 2023 (€131.83 Mil) to Mar. 2024 (€128.24 Mil).

Anavex Life Sciences's annual Ending Cash Position increased from Sep. 2021 (€129.29 Mil) to Sep. 2022 (€150.65 Mil) but then declined from Sep. 2022 (€150.65 Mil) to Sep. 2023 (€141.51 Mil).

Anavex Life Sciences Ending Cash Position Historical Data

The historical data trend for Anavex Life Sciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Ending Cash Position Chart

Anavex Life Sciences Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Ending Cash Position

Get a 7-Day Free Trial

20.15

24.83

129.29

150.65

141.51

Anavex Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															143.34	142.90	141.51	131.83	128.24

Anavex Life Sciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Anavex Life Sciences's Ending Cash Position for the fiscal year that ended in Sep. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	139.761	+	1.748
	=	141.51

Anavex Life Sciences's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	132.264	+	-4.029
	=	128.24

Anavex Life Sciences Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences (STU:12X1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

AVXL:USA 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (STU:12X1) Headlines

No Headlines